Exploring phenotypes of deep vein thrombosis in relation to clinical outcomes beyond recurrence

Autor: Aaron F.J. Iding, Alejandro Pallares Robles, Vincent ten Cate, Hugo ten Cate, Philipp S. Wild, Arina J. ten Cate-Hoek
Přispěvatelé: Biochemie, RS: Carim - B04 Clinical thrombosis and Haemostasis, MUMC+: HVC Trombosedienst (9), Interne Geneeskunde, MUMC+: MA Alg Interne Geneeskunde (9), MUMC+: HVC Trombosezorg (8), MUMC+: HVC Pieken Trombose (9)
Rok vydání: 2023
Předmět:
Zdroj: Journal of Thrombosis and Haemostasis, 21(5), 1238-1247. Wiley
ISSN: 1538-7836
1538-7933
DOI: 10.1016/j.jtha.2023.01.025
Popis: BACKGROUND: Deep vein thrombosis (DVT) is a multifactorial disease with several outcomes, but current classifications solely stratify based on recurrence risk.OBJECTIVES: We aimed to identify DVT phenotypes and assess their relation to recurrent venous thromboembolism (VTE), post-thrombotic syndrome, arterial events, and cancer.PATIENTS/METHODS: Hierarchical clustering was performed on a DVT cohort with up to five years follow-up using 23 baseline characteristics. Phenotypes were summarized by discriminative characteristics. Hazard ratios (HR) were calculated using Cox regression; recurrence risk was adjusted for anticoagulant therapy duration. The study was carried out in accordance with the Declaration of Helsinki and approved by the medical ethics committee.RESULTS: In total 825 patients were clustered into four phenotypes: 1.women using estrogen therapy (n=112); 2.patients with a cardiovascular risk profile (n=268); 3.patients with previous VTE (n=128); 4.patients without discriminant characteristics (n=317). Overall, risks of recurrence, post-thrombotic syndrome, arterial events, and cancer were low in phenotype 1 (reference), intermediate in phenotype 4 (HR 4.6, 1.2, 2.2, 1.8) and high in phenotypes 2 (HR 6.1, 1.6, 4.5, 2.9) and 3 (HR 5.7, 2.5, 2.3, 3.7).CONCLUSIONS: This study identified four distinct phenotypes among DVT patients that are not only associated with increasing recurrence risk, but also with outcomes beyond recurrence. Our results thereby highlight the limitations of current risk stratifications that stratify based on predictors of recurrence risk only. Overall, risks were lowest in women using estrogen therapy and highest in patients with a cardiovascular risk profile. These findings might inform a more personalized approach to clinical management.
Databáze: OpenAIRE
Externí odkaz: